Anteris Technologies Presents Data from 100 DurAVR THV Patients at PCR London Valves MINNEAPOLIS, United States and BRISBANE, Australia 17 November 2025: Anteris Technologies Global Corp. ( Anteris or the Company ) (NASD

Anteris Technologies Presents Data from 100 DurAVR THV Patients at PCR London Valves

MINNEAPOLIS, United States and BRISBANE, Australia 17 November 2025: Anteris Technologies Global Corp. (Anteris or the Company) (NASDAQ: AVR, ASX: AVR) today released 30-day clinical outcomes for the

DurAVR THV in one hundred severe aortic stenosis patients with small aortic annuli (aortic annulus area 404 37mm2). The DurAVR THV demonstrated single digit mean gradients, large effective orifice areas (EOAs),

no moderate or severe paravalvular leaks and no valve related mortality, with 97% freedom from moderate or severe prosthesis-patient mismatch* (PPM) in a cohort of small annuli patients similar to the one reported in the SMART Trial1.

The late-breaking science was presented by Prof. Dr. Ole De Backer at the PCR London Valves conference in London, United Kingdom with simultaneous publication online

in EuroIntervention - Thirty-day outcomes of a novel biomimetic balloon-expandable transcatheter heart valve in patients with small aortic annuli' (DOI: 10.4244/EIJ-D-25-01106).

30-day Results Highlights for 100 DurAVR THV Patients

"The DurAVR THV demonstrated high rates of technical and device success with encouraging 30-day hemodynamic outcomes, including very low PPM in small

annuli patients. These results reflect a unique balance of balloon-expandable benefits characterised by high device success and low pacemaker rates, combined with a hemodynamic profile typically associated with self-expanding platforms," said Prof.

Dr De Backer, The Heart Centre, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark.

"When PPM occurs, patients essentially exchange one obstruction for another.

Moderate to severe PPM is independently associated with reduced survival and increased risk of structural valve deterioration2,3. Achieving 97% freedom from moderate

or severe PPM is clinically relevant, particularly in small annuli patients where the risk of PPM is amplified," said Chris Meduri, M.D., Anteris Chief Medical Officer.

This pooled analysis of 100 patients derived from the ongoing EMBARK study and early feasibility studies (EFS) conducted in the United States and Europe, consists of

patients with small aortic annuli (SAA) treated with the Small size DurAVR THV.

"When we look at the strength of the 30-day outcomes together with the 1-year results presented at TCT, we see a consistent clinical profile that serves as a

potential proxy for the recently initiated PARADIGM Trial. This pooled analysis of 100 patients represents approximately 20% of the planned DurAVR enrolment for the all-comers randomized cohort of PARADIGM. This

consistency across earlier and longer-term patient outcomes reinforces our confidence in DurAVR 's potential as we advance this life-saving technology toward anticipated commercialization," said Vice Chairman and CEO, Wayne Paterson.

The global PARADIGM Trial (ClinicalTrials.gov ID NCT07194265) is a prospective, randomized controlled trial (RCT) which will evaluate the safety and effectiveness of

the DurAVR THV compared to commercially available transcatheter aortic valve replacements (TAVRs) in the treatment of severe aortic stenosis.

*Prosthesis patient mismatch (PPM) happens when a prosthetic valve, after

being implanted, doesn't have a large enough opening (EOA) to accommodate the patient's blood flow needs, based on their body size. The result is higher than expected gradients. PPM affects a significant proportion of transcatheter aortic valve

(TAVR) patients, particularly patients with a small aortic annulus and has been associated with impaired long-term survival following surgical aortic valve replacement (SAVR).

**As defined in VARC-3.

1. Herrmann HC, Mehran R, Blackman DJ, Bailey S, M llmann H, Abdel-Wahab M, Ben Ali W, Mahoney PD, Ruge H, Wood DA, Bleiziffer S, Ramlawi B, Gada H, Petronio AS,

Resor CD, Merhi W, Garcia Del Blanco B, Attizzani GF, Batchelor WB, Gillam LD, Guerrero M, Rogers T, Rovin JD, Szerlip M, Whisenant B, Deeb GM, Grubb KJ, Padang R, Fan MT, Althouse AD, Tch tch D; SMART Trial Investigators. Self-Expanding or

Balloon-Expandable TAVR in Patients with a Small Aortic Annulus. N Engl J Med. 2024 Jun 6;390(21):1959-1971. doi: 10.1056/NEJMoa2312573. Epub 2024 Apr 7. PMID: 38587261.

2. Ferrara J, Theron A, Porto A, Morera P, Luporsi P, Jaussaud N, Gariboldi V, Collart F, Cuisset T, Deharo P. Prosthesis-Patient Mismatch in Small Aortic Annuli:

Self-Expandable vs. Balloon-Expandable Transcatheter Aortic Valve Replacement. J Clin Med. 2022 Apr 1;11(7):1959. doi: 10.3390/jcm11071959. PMID: 35407567; PMCID: PMC8999619.

3. Hahn RT, Pibarot P. Prosthesis-patient mismatch in transcatheter and surgical aortic valve replacement. Ann Cardiothorac Surg. 2024 May 31;13(3):211-223. doi:

10.21037/acs-2023-aae-0166. Epub 2024 Apr 28. PMID: 38841078; PMCID: PMC11148757.

Anteris Technologies Global Corp. (NASDAQ: AVR, ASX: AVR) is a global structural heart company committed to designing, developing, and commercializing cutting-edge

medical devices to restore healthy heart function. Founded in Australia, with a significant presence in Minneapolis, USA, Anteris is a science-driven company with an experienced team of multidisciplinary professionals delivering restorative

solutions to structural heart disease patients.

Anteris' lead product, the DurAVR Transcatheter Heart Valve (THV),

was designed in collaboration with the world's leading interventional cardiologists and cardiac surgeons to treat aortic stenosis - a potentially life-threatening condition

resulting from the narrowing of the aortic valve. The balloon-expandable DurAVR THV is the first biomimetic valve, which is shaped to mimic the performance of a healthy human aortic valve and aims to replicate normal aortic blood flow.

DurAVR THV is made using a single piece of molded ADAPT tissue, Anteris' patented anti-calcification tissue technology. ADAPT tissue, which is FDA-cleared, has been used clinically for over 10 years and

distributed for use in over 55,000 patients worldwide. The DurAVR THV System is comprised of the DurAVR valve, the ADAPT tissue, and the balloon-expandable ComASUR Delivery System.

Forward-Looking Statements

This announcement contains forward-looking statements. Forward-looking statements include all statements that are not historical facts, including the objectives of,

plans for and size of Anteris' studies and trials. Forward-looking statements generally are identified by the words "believe," "project," "expect," "anticipate," "estimate," "intend," "budget," "target," "aim," "strategy," "plan," "guidance,"

"outlook," "may," "should," "could," "will," "would," "will be," "will continue," "will likely result" and similar expressions, although not all forward-looking statements contain these identifying words. These forward-looking statements are

subject to a number of risks, uncertainties, and assumptions, including those described under "Risk Factors" in Anteris' Annual Report on Form 10-K for the fiscal period ended December 31, 2024 that was filed with the Securities and Exchange

Commission and ASX. Readers are cautioned not to put undue reliance on forward-looking statements, and except as required by law, Anteris does not assume any obligation to update any of these forward-looking statements to conform these statements

to actual results or revised expectations.

Authorisation and Additional information

This announcement was authorised for release on the ASX by the Vice Chairman and Chief Executive Officer, Wayne Paterson.

For more information: